Federal Register / Vol. 82, No. 164 / Friday, August 25, 2017 / Notices 40647 

TECHNICAL SERVICES (PTY) 

LIMITED, Namibia; Registration ID 

2001/044 (Namibia) [DPRK3] (Linked 

To: MANSUDAE OVERSEAS PROJECT 

GROUP OF COMPANIES). 

Designated pursuant to sections 

2(a)(vii) and 2(a)(viii) of E.O. 13722, for 

having materially assisted, sponsored, 

or provided financial, material, or 

technological support for, or goods or 

services to or in support of; and for 

being owned or controlled by or having 

acted or purported to act for or on behalf 

of, directly or indirectly, MANSUDAE 

OVERSEAS PROJECT GROUP OF 

COMPANIES, a person whose property 

and interests in property are blocked 

pursuant to E.O. 13722. 

7. QINGDAO CONSTRUCTION 

(NAMIBIA) CC, ERF 338, Platinum 

Street, Prosperita, Windhoek, Namibia; 

P.O. Box 26774, Windhoek, Namibia; 

Registration ID 2008/0598 (Namibia) 

[DPRK3] (Linked To: MANSUDAE 

OVERSEAS PROJECTS 

ARCHITECTURAL AND TECHNICAL 

SERVICES (PTY) LIMITED; Linked To: 

MANSUDAE OVERSEAS PROJECT 

GROUP OF COMPANIES). 

Designated pursuant to section 

2(a)(vii) of E.O. 13722 for having 

materially assisted, sponsored, or 

provided financial, material or 

technological support for, or goods or 

services to or in support of, 

MANSUDAE OVERSEAS PROJECT 

GROUP OF COMPANIES and 

MANSUDAE OVERSEAS PROJECT 

GROUP ARCHITECTURAL AND 

TECHNICAL SERVICES 

(PROPRIETARY) LIMITED, persons 

whose property and interests in 

property are blocked pursuant to E.O. 

13722. 

8. GEFEST–M LLC, Office 401, 

Structure 1, Building 1, Chermyanskaya 

Street, Moscow 127081, Russia; Office 

Space 5, Room 18, Building 5/7 

Rozhdestvenka Street, Moscow 107031, 

Russia [NPWMD] (Linked To: KOREA 

TANGUN TRADING CORPORATION). 

Designated pursuant to section 

1(a)(iii) of E.O. 13382, for having 

provided, or attempted to provide, 

financial, material, technological or 

other support for, or goods or services 

in support of, KOREA TANGUN 

TRADING CORPORATION, a person 

whose property and interests in 

property are blocked pursuant to E.O. 

13382. 

9. MINGZHENG INTERNATIONAL 

TRADING LIMITED, Flat/RM A30 9/F, 

Silvercorp International Tower, 707–713 

Nathan Road, Kowloon, Mong Kok, 

Hong Kong; 224–4 Shifa Da Lu, RM 

1305, Heping District, Shenyang City, 

Liaoning Province, China [NPWMD] 

(Linked To: FOREIGN TRADE BANK 

OF THE DEMOCRATIC PEOPLE’S 

REPUBLIC OF KOREA; Linked To: 

SUN, Wei). 

Designated pursuant to sections 

1(a)(iii) and 1(a)(iv) of E.O. 13382, for 

having provided, or attempted to 

provide, financial, material, 

technological, or other support for, or 

goods or services in support of; and for 

acting or purporting to act for or on 

behalf of, directly or indirectly, 

FOREIGN TRADE BANK, a person 

whose property and interests in 

property are blocked pursuant to E.O. 

13382; and for being owned or 

controlled by SUN WEI, a person whose 

property and interests in property are 

blocked pursuant to E.O. 13382. 

10. DANDONG RICH EARTH 

TRADING CO., LTD., Jiadi Square, 

Number 64, Binjiang Middle Road, 

Room 1001, Building B, Dandong City, 

Liaoning, China [NPWMD] (Linked To: 

KOREA KUMSAN TRADING 

CORPORATION). 

Designated pursuant to section 

1(a)(iii) of E.O. 13382, for having 

provided, or attempted to provide, 

financial, material, technological, or 

other support for, or goods or services 

in support of, KOREA KUMSAN 

TRADING CORPORATION, a person 

whose property and interests in 

property are blocked pursuant to E.O. 

13382. 

Andrea M. Gacki, 

Acting Director, Office of Foreign Assets 

Control. 

[FR Doc. 2017–18042 Filed 8–24–17; 8:45 am] 

BILLING CODE 4810–AL–P 

U.S.-CHINA ECONOMIC AND 

SECURITY REVIEW COMMISSION 

Notice of Open Public Meetings 

AGENCY: U.S.-China Economic and 

Security Review Commission. 

ACTION: Notice of open public meetings. 

SUMMARY: Notice is hereby given of 

meetings of the U.S.-China Economic 

and Security Review Commission to 

review and edit drafts of the 2017 

Annual Report to Congress. The 

Commission is mandated by Congress to 

investigate, assess, and report to 

Congress annually on the ‘‘the national 

security implications of the economic 

relationship between the United States 

and the People’s Republic of China.’’ 

Pursuant to this mandate, the 

Commission will hold public meetings 

to review and edit drafts of the 2017 

Annual Report to Congress. 

DATES: The meetings are scheduled for 

Thursday, September 7, 2017, from 9:00 

a.m. to 5:00 p.m.; Friday, September 8, 

2017, from 9:00 a.m. to 5:00 p.m.; 

Thursday, October 4, 2017, from 9:00 

a.m. to 5:00 p.m.; and Friday, October 

5, 2017, from 9:00 a.m. to 5:00 p.m. 

ADDRESSES: 444 North Capitol Street 

NW., Room 231, Washington, DC 20001. 

Public seating is limited and will be 

available on a ‘‘first-come, first-served’’ 

basis. Reservations are not required to 

attend the meetings. 

FOR FURTHER INFORMATION CONTACT: Any 

member of the public seeking further 

information concerning these meetings 

should contact Alexis Brigmon, 444 

North Capitol Street NW., Suite 602, 

Washington, DC 20001; telephone: 202– 

624–1454, or via email at abrigmon@

uscc.gov. Reservations are not required 

to attend the meetings. 

SUPPLEMENTARY INFORMATION: 

Purpose of Meeting: Pursuant to the 

Commission’s mandate, members of the 

Commission will meet to review and 

edit drafts of the 2017 Annual Report to 

Congress. 

The Commission is subject to the 

Federal Advisory Committee Act 

(FACA) with the enactment of the 

Science, State, Justice, Commerce and 

Related Agencies Appropriations Act, 

2006 that was signed into law on 

November 22, 2005 (Pub. L. 109–108). 

In accordance with FACA, the 

Commission’s meetings to make 

decisions concerning the substance and 

recommendations of its 2017 Annual 

Report to Congress are open to the 

public. 

Topics to Be Discussed: The 

Commission will consider draft report 

sections addressing the following topics: 

• U.S.-China Economic and Trade 

Relations, including: Year in Review: 

Economics Trade; Chinese Investment 

in the United States; and U.S. Access to 

China’s Consumer Market. 

• U.S.-China Security Relations, 

including: Year in Review: Security and 

Foreign Affairs; and Hotspots along 

China’s Maritime Periphery. 

• China and the World, including: 

China and Continental Southeast Asia; 

China and Northeast Asia; China and 

Taiwan; China and Hong Kong; and 

China’s Domestic Information Controls, 

Global Media Influence, and Cyber 

Diplomacy. 

• China’s High Tech Development, 

including China’s Global Pursuit of 

Global Dominance in Computing, 

Robotics, and Biotechnology; and 

China’s Pursuit of Advanced Weapons. 

Required Accessibility Statement: 

These meetings will be open to the 

public. The Commission may recess the 

meetings to address administrative 

issues in closed session. 


sradovich on DSK3GMQ082PROD with NOTICES
40648 Federal Register / Vol. 82, No. 164 / Friday, August 25, 2017 / Notices 

The Commission will also recess the 

meetings around noon for a lunch break. 

At the beginning of the lunch break, the 

Chairman will announce what time the 

meetings will reconvene. 

Authority: Congress created the U.S.- 

China Economic and Security Review 

Commission in 2000 in the National Defense 

Authorization Act (Public Law 106–398), as 

amended by Division P of the Consolidated 

Appropriations Resolution, 2003 (Pub. L. 

108–7), as amended by Pub. L. 109–108 

(November 22, 2005), as amended by Public 

Law 113–291 (December 19, 2014). 

Dated: August 21, 2017. 

Michael Danis, 

Executive Director, U.S.-China Economic and 

Security Review Commission. 

[FR Doc. 2017–18018 Filed 8–24–17; 8:45 am] 

BILLING CODE 1137–00–P 

UNITED STATES SENTENCING 

COMMISSION 

Sentencing Guidelines for United 

States Courts 

AGENCY: United States Sentencing 

Commission. 

ACTION: Request for public comment. 

SUMMARY: In August 2017, the 

Commission indicated that one of its 

policy priorities would be the 

‘‘[c]ontinuation of its multiyear study of 

offenses involving synthetic cathinones 

(such as methylone, MDPV, and 

mephedrone) and synthetic 

cannabinoids (such as JWH–018 and 

AM–2201), as well as 

tetrahydrocannabinol (THC), fentanyl, 

and fentanyl analogues, and 

consideration of appropriate guideline 

amendments, including simplifying the 

determination of the most closely 

related substance under Application 

Note 6 of the Commentary to § 2D1.1.’’ 

See 82 FR 39949 (Aug. 22, 2017). As 

part of its continuing work on this 

priority, the Commission is publishing 

this request for public comment on 

issues related to synthetic cathinones, 

tetrahydrocannabinol (THC), and 

synthetic cannabinoids. The issues for 

comment are set forth in the 

Supplementary Information portion of 

this notice. 

DATES: Public comment regarding the 

issues for comment set forth in this 

notice should be received by the 

Commission not later than October 27, 

2017. 

ADDRESSES: All written comment should 

be sent to the Commission by electronic 

mail or regular mail. The email address 

for public comment is Public_

Comment@ussc.gov. The regular mail 

address for public comment is United 

States Sentencing Commission, One 

Columbus Circle NE., Suite 2–500, 

Washington, DC 20002–8002, Attention: 

Public Affairs. 

FOR FURTHER INFORMATION CONTACT: 

Christine Leonard, Director, Office of 

Legislative and Public Affairs, (202) 

502–4500, pubaffairs@ussc.gov. 

SUPPLEMENTARY INFORMATION: The 

United States Sentencing Commission is 

an independent agency in the judicial 

branch of the United States 

Government. The Commission 

promulgates sentencing guidelines and 

policy statements for federal courts 

pursuant to 28 U.S.C. 994(a). The 

Commission also periodically reviews 

and revises previously promulgated 

guidelines pursuant to 28 U.S.C. 994(o) 

and submits guideline amendments to 

the Congress not later than the first day 

of May each year pursuant to 28 U.S.C. 

994(p). 

In August 2016, the Commission 

indicated that one of its priorities would 

be the ‘‘[s]tudy of offenses involving 

MDMA/Ecstasy, synthetic cannabinoids 

(such as JWH–018 and AM–2201), and 

synthetic cathinones (such as 

Methylone, MDPV, and Mephedrone), 

and consideration of any amendments 

to the Guidelines Manual that may be 

appropriate in light of the information 

obtained from such study.’’ See U.S. 

Sentencing Comm’n, ‘‘Notice of Final 

Priorities,’’ 81 FR 58004 (Aug. 24, 2016). 

On August 17, 2017, the Commission 

revised the priority to study offenses 

involving synthetic cathinones (such as 

methylone, MDPV, and mephedrone) 

and synthetic cannabinoids (such as 

JWH–018 and AM–2201), as well as 

tetrahydrocannabinol (THC), fentanyl, 

and fentanyl analogues. See U.S. 

Sentencing Comm’n, ‘‘Notice of Final 

Priorities,’’ 82 FR 39949 (Aug. 22, 2017). 

The Commission also stated that, as part 

of the study, the Commission will 

consider possible approaches to 

simplify the determination of the most 

closely related substance under 

Application Note 6 of the Commentary 

to § 2D1.1 (Unlawful Manufacturing, 

Importing, Exporting, or Trafficking 

(Including Possession with Intent to 

Commit These Offenses); Attempt or 

Conspiracy). The Commission expects 

to solicit comment several times during 

the study period from experts and other 

members of the public. 

On December 19, 2016, the 

Commission published a notice inviting 

general comment on synthetic 

cathinones (MDPV, methylone, and 

mephedrone) and synthetic 

cannabinoids (JWH–018 and AM–2201), 

as well as about the application of the 

factors the Commission traditionally 

considers when determining the 

marihuana equivalencies for specific 

controlled substances to the substances 

under study. See U.S. Sentencing 

Comm’n, ‘‘Request for Public 

Comment,’’ 81 FR 92021 (Dec. 19, 2016). 

On April 18, 2017, the Commission 

held a public hearing relating to this 

priority. The Commission received 

testimony from experts on the synthetic 

drugs related to the study, including 

testimony about their chemical 

structure, pharmacological effects, 

trafficking patterns, and community 

impact. 

On June 21, 2017, the Commission 

published a second notice requesting 

public comment on issues specifically 

related to MDMA/ecstasy and 

methylone, one of the synthetic 

cathinones included in the 

Commission’s study. See U.S. 

Sentencing Comm’n, ‘‘Request for 

Public Comment,’’ 82 FR 28382 (June 

21, 2017). 

As part of its continuing work on this 

priority, the Commission is publishing 

this third request for public comment. 

The request for public comment 

contains two parts (Part A and Part B). 

Part A focuses on issues related to 

synthetic cathinones. Part B focuses on 

issues related to tetrahydrocannabinol 

(THC) and synthetic cannabinoids. 

In addition to the substance-specific 

topics discussed below, the Commission 

anticipates that its work will continue to 

be guided by the factors the Commission 

traditionally considers when 

determining the marihuana 

equivalencies for specific controlled 

substances, including their chemical 

structure, pharmacological effects, 

legislative and scheduling history, 

potential for addiction and abuse, the 

patterns of abuse and harms associated 

with their abuse, and the patterns of 

trafficking and harms associated with 

their trafficking. 

The Commission will also consider 

possible approaches to simplify the 

determination of the most closely 

related substance under Application 

Note 6 of the Commentary to § 2D1.1. 

The Commission has received comment 

from the public suggesting that 

questions regarding ‘‘the most closely 

related controlled substance’’ arise 

frequently in cases involving the 

substances included in the study, and 

that the Application Note 6 process 

requires courts to hold extensive 

hearings to receive expert testimony on 

behalf of the government and the 

defendant. 

The synthetic cathinones and 

synthetic cannabinoids included in the 

study are not specifically listed in either 

the Drug Quantity Table or the Drug 


sradovich on DSK3GMQ082PROD with NOTICES